8 completed, 3 terminated. 11 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 8, Terminated 3 |
| Phase 1 | 7 | Completed 5, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow CureVac: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose) - SARS-CoV-2, COVID-19 | Phase 2 | Completed | GlaxoSmithKline | 692 | 2023-08-01 | 2025-10-23 |
| A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z - Influenza, Human | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1275 | 2023-04-27 | 2025-07-23 |
| A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older CVnCoV, Placebo, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program - Covid19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | CureVac | 39680 | 2020-12-11 | 2024-04-29 |
| A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine - Coronavirus, Covid19 | Phase 2 | Completed | CureVac | 668 | 2020-09-21 | 2023-09-28 |
| Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Durvalumab, Tremelimumab, BI 1361849 - Metastatic Non-small Cell Lung Cancer, NSCLC | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 61 | 2017-12-20 | 2022-10-10 |
| IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients IMA970A plus CV8102 and Cyclophosphamide - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute, Naples | 22 | 2017-09-18 | 2020-02-05 |
| An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer CV9104, needle free injection device (Tropis®) - Prostate Carcinoma | Phase 2 | Terminated | CureVac | 35 | 2014-06-01 | 2016-06-13 |
| Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer CV9104, Placebo - Prostate Cancer | Phase 1 / Phase 2 | Terminated | CureVac | 197 | 2012-08-01 | 2017-02-17 |
| Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) CV9201 - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | CureVac | 46 | 2009-05-01 | 2018-03-20 |
| RNActive®-Derived Therapeutic Vaccine CV9103 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Terminated | University of Florida | 6 | 2009-05-01 | 2012-04-04 |
| Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease CV9103 - Hormonal Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | CureVac | 48 | 2009-01-01 | 2018-03-20 |
COVID-19 (3) · Carcinoma, Non-Small-Cell Lung (2) · Prostatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Coronavirus Infections (1) · Influenza, Human (1) · Neoplasm Metastasis (1) · Severe Acute Respiratory Syndrome (1)
CVnCoV COVID-19 vaccine (2) · Cyclophosphamide (1) · Hepatitis A Vaccines (1) · Pneumococcal Vaccines (1) · durvalumab (1) · tremelimumab (1)
Germany (6) · United States (4) · Belgium (3) · Spain (3) · Italy (2) · Panama (2) · Peru (2) · Switzerland (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Canada (1) · Colombia (1) · Czechia (1) · Dominican Republic (1)
Alexander Knuth, Prof. Dr. (1) · Arnulf Stenzl, Prof. Dr. (1) · Arnulf Stenzl, Prof. Dr. med. (1) · Jhanelle Gray, MD (1) · Johannes Vieweg, MD FACS (1) · Kurt Miller, Professor (1)
PMID 21150709, PMID 34826381, PMID 35421231, PMID 42647564, PMID 42875683